These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Genomic Characterization of High-Grade Serous Ovarian Cancer: Dissecting Its Molecular Heterogeneity as a Road Towards Effective Therapeutic Strategies. Mittempergher L Curr Oncol Rep; 2016 Jul; 18(7):44. PubMed ID: 27241520 [TBL] [Abstract][Full Text] [Related]
24. Ovarian cancer and the evolution of subtype classifications using transcriptional profiling†. Cook DP; Vanderhyden BC Biol Reprod; 2019 Sep; 101(3):645-658. PubMed ID: 31187121 [TBL] [Abstract][Full Text] [Related]
25. Immunotherapeutic Approaches in Ovarian Cancer. Yoon H; Kim A; Jang H Curr Issues Mol Biol; 2023 Feb; 45(2):1233-1249. PubMed ID: 36826026 [TBL] [Abstract][Full Text] [Related]
26. Precision Oncology of High-Grade Ovarian Cancer Defined through Targeted Sequencing. Wessman S; Fuentes BB; Törngren T; Kvist A; Kokaraki G; Menkens H; Hjerpe E; Hugo Y; Petta TB; Borg Å; Carlson JW Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680387 [TBL] [Abstract][Full Text] [Related]
27. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences. Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK Cells; 2021 Dec; 10(12):. PubMed ID: 34944094 [TBL] [Abstract][Full Text] [Related]
28. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). Ruscito I; Dimitrova D; Vasconcelos I; Gellhaus K; Schwachula T; Bellati F; Zeillinger R; Benedetti-Panici P; Vergote I; Mahner S; Cacsire-Tong D; Concin N; Darb-Esfahani S; Lambrechts S; Sehouli J; Olek S; Braicu EI Eur J Cancer; 2014 Aug; 50(12):2090-8. PubMed ID: 24889916 [TBL] [Abstract][Full Text] [Related]
29. Characterizing TP53 mutations in ovarian carcinomas with and without concurrent BRCA1 or BRCA2 mutations. Ghezelayagh TS; Pennington KP; Norquist BM; Khasnavis N; Radke MR; Kilgore MR; Garcia RL; Lee M; Katz R; Leslie KK; Risques RA; Swisher EM Gynecol Oncol; 2021 Mar; 160(3):786-792. PubMed ID: 33375991 [TBL] [Abstract][Full Text] [Related]
30. Clinical Implications of DNA Repair Defects in High-Grade Serous Ovarian Carcinomas. Milanesio MC; Giordano S; Valabrega G Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455819 [TBL] [Abstract][Full Text] [Related]
31. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. Przybytkowski E; Davis T; Hosny A; Eismann J; Matulonis UA; Wulf GM; Nabavi S BMC Cancer; 2020 Mar; 20(1):197. PubMed ID: 32164626 [TBL] [Abstract][Full Text] [Related]
32. Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice. Dong A; Lu Y; Lu B J Cancer; 2016; 7(11):1441-51. PubMed ID: 27471560 [TBL] [Abstract][Full Text] [Related]
33. Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers. Turchiano A; Loconte DC; De Nola R; Arezzo F; Chiarello G; Pantaleo A; Iacoviello M; Bagnulo R; De Luisi A; Perrelli S; Martino S; Ranieri C; Garganese A; Stella A; Forleo C; Loizzi V; Marinaccio M; Cicinelli E; Cormio G; Resta N Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053526 [TBL] [Abstract][Full Text] [Related]
34. Clinical Impact of Somatic Variants in Homologous Recombination Repair-Related Genes in Ovarian High-Grade Serous Carcinoma. Choi MC; Hwang S; Kim S; Jung SG; Park H; Joo WD; Song SH; Lee C; Kim TH; Kang H; An HJ Cancer Res Treat; 2020 Apr; 52(2):634-644. PubMed ID: 32019284 [TBL] [Abstract][Full Text] [Related]
35. Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targets. da Costa AABA; Baiocchi G Semin Cancer Biol; 2021 Dec; 77():29-41. PubMed ID: 33161141 [TBL] [Abstract][Full Text] [Related]
36. Platform-Independent Classification System to Predict Molecular Subtypes of High-Grade Serous Ovarian Carcinoma. Shilpi A; Kandpal M; Ji Y; Seagle BL; Shahabi S; Davuluri RV JCO Clin Cancer Inform; 2019 Apr; 3():1-9. PubMed ID: 31002564 [TBL] [Abstract][Full Text] [Related]
37. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer. Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492 [TBL] [Abstract][Full Text] [Related]
38. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study. Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988 [TBL] [Abstract][Full Text] [Related]
39. Molecular profiling and molecular classification of endometrioid ovarian carcinomas. Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883 [TBL] [Abstract][Full Text] [Related]
40. Molecular Classification of Epithelial Ovarian Cancer Based on Methylation Profiling: Evidence for Survival Heterogeneity. Bodelon C; Killian JK; Sampson JN; Anderson WF; Matsuno R; Brinton LA; Lissowska J; Anglesio MS; Bowtell DDL; Doherty JA; Ramus SJ; Talhouk A; Sherman ME; Wentzensen N Clin Cancer Res; 2019 Oct; 25(19):5937-5946. PubMed ID: 31142506 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]